Antengene

Executive Summary

Antengene is a commercial-stage biopharmaceutical company based in Shanghai, China, focused on developing and commercializing innovative therapies for oncology and immunology. Founded in 2016, the company has leveraged a strategic partnership with Celgene (now part of Bristol Myers Squibb) to advance its pipeline and successfully launched its first product in China. Antengene employs a global development and commercialization strategy to address significant unmet medical needs in hematologic malignancies and solid tumors. As a public company with 200-500 employees, it has established itself as a key player in the Chinese biopharma landscape, though its pipeline details remain limited. The company's ability to generate near-term value hinges on advancing its pipeline candidates, securing regulatory approvals, and expanding its partnership network.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval decision for lead pipeline candidate in China70% success
• Q4 2026Publication of Phase 2/3 clinical data for a key oncology asset60% success
• TBDNew strategic partnership or licensing deal for pipeline expansion50% success